Estimation of trochanteric soft tissue thickness from dual-energy X-ray absorptiometry.

Low body mass index is considered to be an important risk factor for fractures in postmenopausal women, in part reflecting its association with lower bone mineral density (BMD). In contrast, obesity is thought to be protective against fracture because of higher BMD and reduced transmitted force of falls as a result of soft tissue padding. Dual-energy X-ray absorptiometry (DXA) is most widely used for the assessment of osteoporosis. We hypothesized that trochanteric soft tissue thickness, as measured directly on whole-body DXA scans, could be estimated using the regional measures of anteroposterior tissue thickness from hip and spine DXA. We identified 376 adult patients who underwent DXA evaluation of the lumbar spine, hip, and whole body at the same visit. The population was randomly divided into 2 equal-sized subgroups, one used to derive prediction equations for trochanteric soft tissue thickness and the other for independent validation. Compared with the actual measurement from the whole-body scans in the validation cohort, the DXA-based estimate gave an unbiased prediction of trochanteric soft tissue thickness (adjusted R² was 0.60 with a standard error of the estimate of 1.35cm), which was significantly better than estimation obtained without DXA information (p < 0.001). Area under the curve discrimination for trochanteric soft tissue thickness in the lowest and highest tertiles was 0.901 (95% confidence interval: 0.849-0.953) and 0.859 (95% confidence interval: 0.805-0.915), respectively. Model-based prediction of trochanteric soft tissue thickness in the lowest and highest tertiles had sensitivities of 78.5% and 91.9% and specificities of 64.4% and 86.8%, respectively. We conclude that regional DXA scans of the spine and hip can be used to estimate the trochanteric soft tissue thickness.

Preoperative therapeutic apheresis for severe medically refractory amiodarone-induced thyrotoxicosis: a case report.

INTRODUCTION: Amiodarone is associated with thyroid dysfunction and life-threatening thyrotoxicosis. In medically refractory cases, or where medical therapy is contraindicated, thyroidectomy may be required. To decrease perioperative thyroid storm and to reduce overall surgical risk, apheresis may be considered preoperatively to restore euthyroidism. CASE DESCRIPTION: We report a 46-year-old female with a history of cardiac arrhythmia and tachycardia-induced cardiomyopathy for which she received amiodarone. Months after discontinuation of amiodarone, the patient presented with wide complex tachycardia and symptoms of thyrotoxicosis. Laboratory testing confirmed severe thyrotoxicosis which was subsequently refractory to medical therapy. Total thyroidectomy was required. Following a total of 10 apheresis treatments, thyroid hormone levels were reduced to near normal levels and the patient's symptoms improved. Thyroidectomy was performed without intraoperative or postoperative complication. DISCUSSION: In the setting of life-threatening, medically refractory amiodarone-induced thyrotoxicosis, therapeutic apheresis can effectively reduce thyroid hormone levels and restore a state of clinical and biochemical euthyroidism.

Insulin secretion in liver transplant recipients following conversion to a prolonged release tacrolimus formulation.

Background: Post liver transplant diabetes mellitus (PLTDM) occurs in 10-40% of liver transplant recipients and is associated with increased morbidity and mortality. An important cause of PLTDM is tacrolimus induced, concentration-dependent, inhibition of insulin secretion. Objective: To determine if a newly licenced formulation of tacrolimus (Envarsus-PA), which achieves peak tacrolimus concentrations 20-30% lower than other tacrolimus formulations has less of an inhibitory effect on insulin secretion. Methods: Homeostatic model assessment (HOMA) for insulin secretion (HOMA-S) values and c-peptide levels were determined in 19 adult liver transplant recipients while being maintained on immediate- or slow-release tacrolimus formulations and repeated a minimum of 30 days following conversion to Envarsus-PA. Results: Insulin secretion was unchanged following conversion to Envarsus-PA (HOMA-S pre-conversion: 154 ± 133 vs. 129 ± 75, post-conversion [p = 0.32], and c-peptide levels; 1059 ± 602 and 934 ± 463 respectively, p = 0.42). Fasting blood glucose (FBG) and hemoglobin A1c (HbA1c) levels were also unchanged (FBG 5.7 ± 0.8 pre-conversion vs. 5.6 ± 0.7 post-conversion; p = 0.36 and HbA1c 4.9±1.2 pre-conversion versus 5.5±0.2 post-conversion, p = 0.34). Conclusions: Envarsus-PA had no significant effect on insulin secretion or glucose homeostasis beyond that associated with other tacrolimus formulations in adult liver transplant recipients.